IVERIC bio, Inc. announced the election of Christine Ann Miller to its Board of Directors, effective immediately. A global pharmaceutical veteran with more than 20 years of experience in life sciences, Ms. Miller is President and Chief Executive Officer of Melinta Therapeutics LLC, a company focused on the development and commercialization of innovative therapies for acute and life-threatening illnesses. Prior to her role at Melinta Therapeutics, where she also serves on the Board of Directors, Ms. Miller led the global and U.S. product portfolio for Sandoz, a $10 billion division of Novartis, where she was responsible for transitioning the portfolio toward rapid-growth and higher-margin segments such as complex generics and value-added medicines, while continuing to build the branded generics business.
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |